Martindale Pharma improves Aurum pre-filled syringe packaging
To ensure ease of use and improve patient safety
The Aurum syringes are used for on-the-spot administration of drugs where high visibility and simple drug identification is crucial.
The Brentwood, Essex-based firm has redesigned the range to enhance ease of use and help improve patient safety. Specific improvements include new colour-differentiated packaging; colour-differentiated translucent boxes that confirm contents; and colour-differentiated labels. In addition the firm has improved tamper-evident labels and the packaging is latex-free and Luer Lock fitting.
The firm says its new colour-differentiated packaging meets national and international colour differentiation standards on syringe labelling and also the Royal College of Anaesthetists recommendations on syringe labelling in critical care.
You may also like
Packaging
Coding and marking innovation takes centre stage at Interpack 2026
Read moreLinx Printing Technologies and Domino Printing Sciences are unveiling systems that promise to address longstanding production challenges, including those specific to pharmaceutical and life sciences manufacturing.
Trending Articles
You may also like
Packaging
Amarox recalls sertraline batch after citalopram blister strips found inside sealed cartons
The MHRA has issued a class two recall of one batch of Amarox's sertraline 100 mg film-coated tablets following a secondary packaging error that resulted in citalopram 40 mg blister strips being included in sealed cartons
Regulatory
FDA approves AstraZeneca's Breztri Aerosphere as first single-inhaler triple therapy for asthma
AstraZeneca has received FDA approval to extend Breztri Aerosphere's indication to include maintenance treatment of asthma in patients aged 12 and older, based on Phase III KALOS and LOGOS trial data showing statistically significant improvements in lung function
Regulatory
WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants
The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Regulatory
FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus
AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion